SCHEMBL5652346

SCHEMBL5652346

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccc(OC)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
TP53 P04637 4/20 0.43
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647395 0.96 MAPT (0.50) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL5650136 0.93 MAPT (0.51) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5653998 0.92 MAPT (0.48) MAPTCYP1A2CYP2C9CYP2C19GABRA2
SCHEMBL5653063 0.90 ALDH1A1 (0.52) MAPTALDH1A1MEN1KMT2ATP53
SCHEMBL5652325 0.90 MAPT (0.47) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5648531 0.90 ALDH1A1 (0.47) MAPTCYP1A2CYP2C19GABRA2GABRB2
SCHEMBL5653552 0.89 ALDH1A1 (0.48) MAPTALDH1A1MEN1KMT2ATP53
SCHEMBL5650867 0.88 MAPT (0.47) MAPTCYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL5652232 0.87 FNTA (0.49) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5654243 0.87 MAPT (0.46) MAPTCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MAPT 3795/4885CYP1A2 687/4885CYP3A4 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.